Apr 1, 2018

New results show that Edixomed’s revolutionary new wound care system, EDX110, can heal diabetic foot ulcers dramatically faster and more effectively than current standard care.

“Diabetic foot ulcers are notoriously hard to heal and are the leading cause of diabetes-related amputations in the UK. The findings reported today provide an essential step forward in developing solutions for the effective management of these chronic wounds,” said Professor Michael Edmonds, Principal Investigator, King’s College Hospital, London. “Reducing infection and accelerating healing could significantly contribute to a reduction in the number of avoidable amputations. EDX110 represents a major step forward in best practice care.”

EDX110 provides a protective and cushioning layer that uniquely absorbs fluid while providing a moist environment and generating nitric oxide. The findings of this study support the unique potential of EDX110’s core technology: a sustained-release nitric oxide generating platform, that can be delivered as a dressing, liquid, gel or inhaled spray, with potential application in a variety of serious, underserved conditions and public health challenges, such as antimicrobial resistance (AMR).

Results from the pivotal clinical study, conducted in major UK treatment centres and involving 148 diabetic foot ulcers, showed that in 12 weeks, EDX110 reduced ulcer size by almost double the amount standard-of-care achieved (89% vs. 47%). EDX110 also increased the number of completely healed ulcers by more than 50% (49% vs. 30%), nearly doubled the complete healing of infected ulcers (45% vs. 23%) and significantly reduced hospitalisations and serious adverse events related to the ulcer, compared with standard-of-care at 12 weeks.

Through its novel mode-of-action, Edixomed’s unique technology safely harnesses a key molecule in the body’s own defences, nitric oxide, to amplify the body’s own response in fighting infection, improving healing and potentially increasing the activity of any prescribed antibiotic. Laboratory tests have shown EDX110 rapidly and safely kills bacteria, viruses and fungi, including several deadly antibiotic-resistant infections, such as MRSA and E. Coli.

30 TECHNOLOGY is developing and defining new models of care to treat many serious medical conditions by enhancing the body’s healing and defence mechanisms.

30 TECHNOLOGY Therapeutic Nitric Oxide